Direct immunofluorescence of scabies lesions revealed IgM, IgA, C3, and fibrin in the cornified layer of the epidermis, dermoepidermal junction, and papillary dermal vessels. The granular deposits of IgM and IgG in the dermoepidermal junction had a pattern similar to that found in lupus erythematosus. These findings support a humoral immune response secondary to scabetic infestation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0190-9622(80)80184-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Beneficial Effects of Tilapia Fish Skin on Excisional Skin Wound Healing in a Type I Diabetic Rat Model.
J Biomed Mater Res B Appl Biomater
January 2025
Department of Surgery, Anesthesiology and Radiology, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt.
IntroductionProlonged hyperglycemia in diabetic patients often impairs wound healing, leading to chronic infections and complications. This study aimed to evaluate the potential of fresh Tilapia fish skin as a treatment to enhance wound healing in diabetic rats. MethodsThirty-nine healthy adult albino rats, weighing between 150 and 200 g, were divided into three groups: non-diabetic rats with untreated wounds [C-], diabetic rats with untreated wounds [C+], and diabetic rats treated with fresh Tilapia skin [TT].
View Article and Find Full Text PDFBullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230.
Front Immunol
December 2024
Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy.
Background: Bullous pemphigoid (BP) and mucous membrane pemphigoid (MMP) are rare autoimmune blistering disorders characterized by autoantibodies (autoAbs) targeting dermo-epidermal junction components such as BP180 and BP230. The differential diagnosis, based on both the time of appearance and the extension of cutaneous and/or mucosal lesions, is crucial to distinguish these diseases for improving therapy outcomes and delineating the correct prognosis; however, in some cases, it can be challenging. In addition, negative results obtained by commercially available enzyme-linked immunosorbent assays (ELISAs) with BP and MMP sera, especially from patients with ocular involvement, often delay diagnosis and treatment, leading to a greater risk of poor outcomes.
View Article and Find Full Text PDFBackground: Skin atrophy and fragility associated with Dermatoporosis result from chronic extracellular matrix (ECM) degradation. A current marketed product, ReFORM & RePAIR COMPLEX with TriHex Technology® (R&R, Alastin Skincare, Inc.), contains actives that aid in recycling the ECM with new matrix components that have been found to be deficient in patients with DP.
View Article and Find Full Text PDFSystemic treatment of recessive dystrophic epidermolysis bullosa with mesenchymal stromal cells: a scoping review of the literature and conclusions for future clinical research.
J Dermatolog Treat
December 2024
RHEACELL GmbH & Co. KG, Heidelberg, Germany.
Article Synopsis
- - Mesenchymal stromal cells (MSCs) show promise as a treatment for recessive dystrophic epidermolysis bullosa (RDEB), potentially aiding in tissue repair and improving collagen VII at the skin layer junction.
- - A review of clinical research from PubMed revealed that six early-phase studies and one case report involved 59 patients receiving MSC infusions, with only a few mild adverse events and overall positive feedback on skin improvements and quality of life.
- - While the evidence is still limited due to the challenges of studying rare diseases, the results suggest MSC therapy could benefit RDEB patients, warranting further investigation into this treatment method.
Linear IgA bullous dermatosis in a latin adolescent treated with cyclosporine and prednisone.
Bol Med Hosp Infant Mex
October 2024
Pediatric Dermatology Service, General Hospital of Mexico Dr. Eduardo Liceaga, Ministry of Health. Mexico City, Mexico.
Article Synopsis
- Linear IgA bullous dermatosis (LABD) is a rare autoimmune condition typically treated with dapsone, though other immunomodulators are used if needed.
- A recent case involved a 12-year-old boy with a severe skin condition diagnosed as LABD, confirmed through biopsy, and treated effectively with prednisone and cyclosporine.
- The patient's condition improved significantly within 2 weeks, leading to further maintenance therapy with cyclosporine after initial treatments were paused due to side effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!